Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.

Altorki, N K

Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jul 2003 - 2645-50 p. digital

Publication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

0732-183X

10.1200/JCO.2003.07.127 doi


Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Carboplatin--administration & dosage
Carcinoma, Non-Small-Cell Lung--drug therapy
Celecoxib
Chemotherapy, Adjuvant
Cyclooxygenase Inhibitors--administration & dosage
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Synergism
Female
Follow-Up Studies
Humans
Lung Neoplasms--drug therapy
Male
Maximum Tolerated Dose
Middle Aged
Paclitaxel--administration & dosage
Pneumonectomy
Preoperative Care--methods
Pyrazoles
Sulfonamides--administration & dosage
Survival Analysis
Treatment Outcome